OVIPIN

Article

Ovipin: a chicken eggs antibiotic agent

Sandra Regina dos SANTOS^{1,2,3,*}; Antonio MIRANDA^{1,2}; Pedro Ismael da SILVA JUNIOR^{1,3,*}

¹ Biological Sciences (Molecular Biology) Post-Graduation Program - UNIFESP

² Department of Biophysics, UNIFESP, São Paulo CEP 04023-062, Brazil; amiranda@unifesp.br

³ Laboratory for Applied Toxinology - Center of Toxins, Immune-Response and Cell Signaling

– CeTICS/CEPID, Butantan Institute, São Paulo CEP 05503-900, SP, Brazil

*Correspondence: sandrasantos111@gmail.com; Tel.: +55-15-98167-9581;

pijsr@butantan.gov.br; Tel.: +55-11-2627-9731

Abstract: The intensive and indiscriminate use of antibiotic has increased cases of microorganisms resistance and becoming a worldwide public health problem. In the last years, from natural sources such as hen's egg, have received special attention in the discovery of new bioactive compounds. This study aims to identify and characterize a new peptide from chicken egg of *Gallus gallus domesticus*. The peptide was isolated and purified by high-performance liquid chromatography (HPLC), and its antimicrobial activity was evaluated through liquid growth inhibition assays. The peptide, Ovipin, presented antimicrobial activity against Gram-positive bacteria, Filamentous fungus and Yeast, not cause significant hemolytic effect against human erythrocytes. The molecular weight and amino acid sequence of the peptide was determined by mass spectrometry (MS). Ovipin primary sequence is YVSPVAIVKGLNIPL and a molecular weight of 1,581.94 Da. Ovipin shows 100% and 93.3%, respectively, sequence similarity with the fragments Apolipoprotein B of *Gallus gallus* and Apolipoprotein B of five others species of Aves. Our data suggest that Ovipin peptide could be a potential therapeutic candidate to be used in combination with other antimicrobial molecules or an alternative led compound for substitution the conventional antibiotics against infections developed by resistant microorganisms.

Keywords: 1: Ovipin; 2: chicken eggs; 3: antimicrobial; 4: peptide; 5: AMPs.

1. Introduction

Antibiotics are natural or synthetic compounds that can inhibit the growth or to induce microorganisms (bacteria or fungus) death (Guimarães et al., 2010), but the increase in cases of infection triggered by resistant microorganisms is difficult to treat with conventional antibiotics available. The antibiotic resistance problem has motivated the search for new molecules for infection control such as finding novel non-traditional antibiotic sources or elaborating combinations between commercial available antibiotics to generate synergistic effects (Garcia et al., 2013).

In this regard, antimicrobial peptides (AMPs) are evolutionarily conserved innate immune defense system and are produced by many organisms (Peters et al., 2010), such as Prokaryotes

(e.g., bacteria) and Eukaryotes (e.g., protozoan, fungi, plants, insects and animals) (**Izadpanah & Gallo, 2005; Bahar & Ren, 2013**). These molecules play an important role, as they act as a first-line defense system and can be constitutively present or induced through external stimuli (**Mookherjee & Hancock, 2007**). They are widely studied by presenting a fast and broad spectrum of action against Gram-positive and Gram-negative bacteria, fungi, protozoa and viruses and act as a cytotoxic component against some types of cancers (**Kang et al., 2014; Andreu & Rivas, 1998; Cruz et al., 2014**). Thus presenting the ability to inhibit growth or kill multi-resistant microorganism (**Peters et al., 2010**).

Antimicrobial peptides (AMPs) are small (weight <10 kDa) and in general amphipathic molecules, positively or negatively charged with amino acids sequences diversity (five to 100 amino acids), (**Bahar & Ren, 2013; Cruz et al., 2014**). They are selective for prokaryotic membranes and act on the cell membrane-disruptive of microorganisms through electrostatic interactions and show low natural resistance. The positive charges present on the peptide chains favor an electrostatic interaction with the negative charges of the phospholipids present on the surface of the microorganism's membranes (**Zasloff, 2002**). This electrostatic followed by an hydrophobic interactions causes an increase in the permeability of the membrane and leading to a spillage of the internal content of the microorganism (**Shai, 1999**). Some peptides have no action on the cell membrane, but rather they cross this membrane and act on intracellular targets, which can interfere in crucial processes for the growth and development of microorganisms. Thus, these AMPs can inhibit cell wall formation, block nucleic acid synthesis processes, prevent protein synthesis or inhibit some enzyme activity (**Brogden, 2005**).

On the other hand, in the last years has also growth the interest in the search for bioactive molecules in food sources. The functional foods contain amounts and types of bioactive compounds different, which provide health benefits and may decrease the development of chronic diseases (**Gil-Chávez et al., 2013; Rutherford-Markwick, 2012**). As a natural source, the chicken eggs with their diversity of structure and variety of components are increasingly becoming targets of research in health or biotechnology (**Hancock & Sahl, 2006**). Chicken eggs is an important dietary source because it is rich in proteins, lipids, vitamins and minerals, but which are associated with other functions such as defense to inhibit the invasion and proliferation of pathogens (**Kovacs-Nolan et al., 2005**). As example, the Lysozyme is one of the main proteins of the egg is that it has a potent antimicrobial action. This protein has bactericidal activity against Gram-positive bacteria, breaking the beta 1-4 bond between N-acetylmuramic acid and N-acetylglucosamine

acid of the cell wall resulting in the inhibition and death of this microorganism (**Ercan and Demirci, 2016**).

Then, the discovery of new AMPs from natural sources is of great importance for public health, since these molecules are pharmacological candidates due to their effective antimicrobial activity and low resistance rates (**Peters et al., 2010**). The aim of this work is to performed the bioprospecting on chicken eggs of specie *Gallus gallus domesticus*, with focus in the discovery of new antimicrobial peptides with great potential to act against microorganisms, especially microorganisms that have already developed some resistance mechanism.

2. Materials and Methods

Chicken Extract preparation

In this study chicken eggs without the shell of the species *Gallus gallus domesticus* were utilized. They were purchased from the commercial market network in the city of São Paulo/SP.

The total chicken eggs crude were submitted to acid extraction in the presence of Acetic Acid 2 mol.L⁻¹, with constant agitation for 60 min at 4° C. After the stirring time, the insoluble material was separated by centrifugation at 3113 x g for 30 min and the supernatant obtained was injected into coupled Sep-Pack₁₈ cartridges (Waters Associates – 20 cc vac cartridge, 5 g, and particle weight 55-105 µm) equilibrated in trifluoroacetic acid (0,1% TFA). The supernatant was pre-fractionated in three different acetonitrile (ACN) concentrations (5%, 40%, and 80% of ACN), using vacuum manifold system equipment (SPE 12 positions aho 6023 - Phenomenex) and then were lyophilized.

Fractionation of Antimicrobial Peptides

The fractions, 5%, 40% and 80% of ACN with 2 g each, were reconstituted in 5 mL 0.1% TFA and subjected by reverse-phase high-performance liquid chromatography (RP-HPLC) was carried out at room temperature on a Shimadzu LC-8A system. The column was a Shim-Pack Preparative ODS C-18 (20 mm x 250 mm; particle weight 10 µm; pore weight 300 Å). The elution was performed with a linear ACN gradient, equilibrated in 0.1% TFA for 60 min at a flow rate of 8.0 mL/min (0 to 20%) for the fraction eluted in 5%, 2 to 60% for the fraction in 40%, and 20 to 80% fraction eluted in 80%. The ultraviolet (UV) absorbance of the effluent was monitored at 225 nm.

The fractions were manually collected, were vacuum-dried and suspended in 1 mL in ultrapure water for antimicrobial activity assays. No fractions with antimicrobial activity were identified in the samples eluted in 5%, 40% of ACN.

The molecule described in this work, fraction 21, was subjected to a second step of fractionation using linear gradient of ACN (39 to 49%) with 0,05% TFA at a flow rate of 2 mL/min for 60 min on the same column Shim-Pack Preparative ODS C-18 (20 mm x 250 mm; particle weight 10 µm; pore weight 300 Å). The fractions were hand-collected, were vacuum-dried, suspended in 500 µL in ultrapure water and it was quantified based on absorbance 205 nm using a NanoDrop 2000 spectrophotometer (Thermo Fischer Scientific, Waltham, MA, USA).

Microorganisms

Fungal and bacterial strains were obtained and stored in the freezer at -80°C in the Laboratory for Applied Toxinology (LETA), of the Butantan Institute (São Paulo, Brazil). *Staphylococcus aureus* ATCC 29213 (Gram-positive bacteria), *Escherichia coli* D31 (Gram-negative bacteria); *Aspergillus niger* (Filamentous fungus – isolated from bread); and *Cryptococcus neoformans* yeast strain A serotype (CFP registration 55 (WM 148 = VNI) were used. The *Cryptococcus neoformans* strain was granted by Dra. Marcia Melhem from the Adolfo Lutz Institute, Brazil - São Paulo.

Antimicrobial Assays and Minimal Inhibitory Concentration (MIC)

Antimicrobial activities of the fractions were evaluated by a liquid growth inhibition assay (Bulet et al., 1993). A suspension of the microorganisms collected in the mid-logarithmic growth phase was used. Bacteria strains were cultured in poor broth nutrient medium (PB: 1.0 g peptone in 100 mL of water containing 86 mM NaCl at pH 7.4; 217 mOsM); for the fungi and yeast strains were cultured in potato dextrose broth (1/2-strength PDB) (1.2 g potato dextrose in 100 mL of H₂O at pH 5.0; 79 mOsM).

Determination of antimicrobial activity was performed using 5-fold microtiter broth dilution assay in 96-well sterile plates at a final volume of 100 µL. A mid-log phase culture were diluted to a final concentration of 5 x 10⁴ CFU/mL for bacteria and 5 x 10⁵ CFU/mL for fungus and yeast (Bulet, 2008; Hetru and Bulet, 1997). Sterile water and PB or PDB were used as growth control, and Streptomycin antibiotic (10.0 mg/mL) was used as growth inhibition control. Microtiter plate

were incubated for 18 and 24 h for bacteria and fungi/yeast, respectively, at 30°C; growth inhibition was determined by measuring absorbance at 595 nm.

The minimum inhibitory concentration (MIC) are expressed as the interval of the concentration [a]–[b], where [a] is the highest tested concentration at which the microorganism grow, and [b] is the lowest concentration which causes a growth inhibition of 100% (Bulet et al., 1993). The assay was performed using a serial dilution and duplicate in 96-well sterile plate; at 20 µL stock solution was used in each microtiter plate well and added to 80 µL of the microorganism dilution (Silva et al., 2000; Lorenzini et al., 2003; Riciluca et al., 2012).

Determination of Hemolytic Activity

The hemolytic activity of the fractions with antimicrobial activity was assessed against human erythrocytes from a health adult donor. The Ethics Committee was the University of São Paulo School of Medicine (USP - FMUSP), n° 18794419.7.0000.0065. The erythrocytes were collected in 0.15 M citrate buffer, pH 7.4, and washed three times by centrifugation (700 x g, 10 min, 4°C) with 0.15 M phosphate buffer saline (PBS – 35 mM phosphate buffer, 0.15 M NaCl, pH 7.4), and resuspended in PBS to a final 3% (v/v) concentration.

Aliquots of 50 µL of each fraction were added to 50 µL of 3% (v/v) suspension erythrocytes in the well of U – shaped bottom plates and incubated for 1h at 37° C (with a final volume of 100 µL). The supernatant was first collected and hemolysis was measuring the absorbance at 405 nm of each well in a Victor³ (1420 Multilabel Counter/ Victor³, Perkin Elmer). The hemolysis percentage was expressed in relation to a 100% lysis control (erythrocytes incubated with 0.1% triton X-100) (Sigma-Aldrich, St. Louis, MO, USA); PBS was used as negative control. The fractions was tested serial dilution and duplicate, and calculation was made according to the following equation: %hemolysis = (Abs sample – Abs negative)/(Abs positive – Abs negative) (Riciluca et al., 2012; Díaz-Roa et al., 2018; Segura and Silva Junior, 2018).

Sodium Dodecyl Sulfate-Polyacrylamide Gel (SDS-PAGE)

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-Page) was carried out. This experiment was performed, with modifications, based on the protocol described by Laemmli (1970). The fraction Ovipin (455 µg) were analyzed under non-reducing conditions (without the presence β-mercaptoetanol) and diluted in four times concentrated buffer (250 mmol.L⁻¹ Tris-HCl

pH 6.8; 300 mmol.L⁻¹ SDS; 1 mmol.L⁻¹ bromophenol blue; 40% glycerol), and heated at 90° C for about 2 minutes. The stacking gel and the running gel were prepared in the concentrations 4.5% and 12% of the polyacrylamide, respectively. The constant voltage and temperature utilized was 120 V at 4° C, and the total running time was 3 h. As a molecular weight marker was used See Blue (Thermo Fisher Scientific Inc.). And the proteins were stained with Coomassie Blue R-250 (Laemmli,1970).

Mass Spectrometry

The fractions that showed antimicrobial activity were analyzed by positive mode mass spectrometry LC-MS/MS on a LTQ XL (Thermo Scientific). The fractions (10 µL of which) were concentrated and resuspended in 10 µL Formic Acid 0,1%. The liquid chromatography was performed in a C18 column (13 cm; 75 µm, i. d.x 100 mm – 3 µm from Waters), using a 5 to 95%B in 25 minutes with solvents A: 15% in acidified water (0,1% TFA) and B: 95% in acidified water (0.1% TFA) for 2 min; with flow of 300 nL/min, voltage of 2.5 kV at 200°C. The full scan was performed with m/z of 100 a 2000, occurring MS/MS–CID, and parameters of five most intense ions, with isolation width of 2 m/z at CID (collision energy at 35).

Database Search

The resulting spectra in “*.RAW*”, format were collected and processed using MSconvert software (Chambers et al., 2012). Thus, they were converted to the mascot generic format (“*.MGF”) and thus analyzed into database searches using the Mascot tool (Perkins et al., 1999). The MS/MS peak list files were submitted to an in – house version of the Mascot server (Matrix Science, United States) and screened against the Uniprot database. PEAKS Studio Software (version 8.5, Bioinformatics Solutions Inc., Waterloo, Ontario, Canada) *de novo* sequencing/database search used for establishing sequence. Analysis involved 10 ppm error tolerance for precursor ions and 0.6 Da for fragment ions. Oxidation was considered a variable modification.

The physicochemical parameters of which the fraction (such as the total number of positively and negatively charged residues, molecular weight, and theoretical pI) were calculated

using the ProtParam tool, available through the portal ExPASy of the Swiss Institute of Bioinformatics website (<https://web.expasy.org/protparam/>) (Gasteiger et al., 2005).

3. Results

Fractionation of Peptides from the Extract of the Chicken Eggs

After acid extraction of the crude extract from the chicken eggs *Gallus gallus domesticus*. The acid extract was applied to Sep-Pak® C18 cartridges for pre-fractionation. The supernatant were eluted by three successive concentrations of acetonitrile (ACN) (5%, 40% and 80%) in acidified water (0.1% TFA). All the material at 80% ACN was subjected and analyzed by RP-HPLC (Figure 1A), and the fractions obtained was lyophilized, suspended in ultrapure water (1 mL) and tested against *Staphylococcus aureus*, *Escherichia coli*, *Aspergillus niger*, and *Cryptococcus neoformans* in a liquid growth inhibitory assay. The searched for the eluted 80% ACN showed the presence of six fractions (9, 11, 20, 21, 22 and 24) with antimicrobial activity (Table 1).

Table 1. Antimicrobial activity fractions from elution 80% ACN Chicken eggs.

Fractions	Microorganisms			
	Fungus		Bacteria	
	Filamentous	Yeast	Gram-positive	Gram-negative
	<i>A. niger</i>	<i>C. neoformans</i>	<i>S. aureus</i>	<i>E. coli</i>
9	-	+	-	-
11	+	+	-	-
20	+	+	+	+
21	+	+	+	+
22	+	+	+	+
24	+	+	-	-

Symbol (+) fraction showed antimicrobial activity; Symbol (-) fraction do not showed antimicrobial activity.

FIGURE 1 | Reversed-phase high-performance liquid chromatograph (RP-HPLC) of the Chicken Eggs *Gallus gallus domesticus* extract eluted with 80% acetonitrile (ACN). After the pre-fractionation in a Sep-Pak C18 column, the fraction was eluted with 80% ACN were subjected to a Shim-Pack ODS C18 (20 x 250 mm, 300 Å, 10 µm); Solvents System: Solvent A: 0.1% TFA/H₂O and Solvent B: 0.1%TFA/ACN with a linear gradient 20% to 80% ACN, 60 min at 8 mL/min flow rate. (A)The fraction 21 indicated by an asterisk (*) had antimicrobial activity against microorganisms tested. (B) Ovipin, indicated with an arrow, using same column and solvents system: Solvent A: 0.05% TFA/H₂O and Solvent B: 0.05%TFA/ACN. Ovipin was eluted from linear gradient 39% to 49% ACN, for 60 min at 2 mL/min flow rate. Both runs the absorbance was monitored at 225 nm.

Antimicrobial Activity and Minimum Inhibitory Concentration (MIC)

The antimicrobial activity occurred in the fraction 21 eluted with retention time range of 32.7-34.1 min (**Figure 1A**). This fraction was submitted to a second step of fractionation and showed only one a pronounced antimicrobial fraction: named Ovipin (**Figure 1B**). The name to choice for which fraction referring the chicken eggs species *Galus gallus domesticus*.

The concentration of Ovipin peptide was determined based on the Lambert-Beer Law using the molar extinction coefficient at 205 nm absorption (**Anthis and Clore, 2013**), obtained using the Protein Parameter Calculator tool available at the Nick Anthis website (<http://nickanthis.com/tools/a205.html>; accessed on 15 September 2021)

Ovipin peptide inhibited the growth of *M. luteus* A270 1.94 µM (2.84 µg/mL), *A. niger* 31.01 µM (45.5 µg/mL), *C. neoformans* VNI (WM 148) 15.51 µM (22.75 µg/mL) (**Table 2**).

Table 2. Antimicrobial activity spectrum of Ovipin peptide.

Microorganisms	MIC (μM ($\mu\text{g/mL}$)) ¹
Gram-positive bacteria	
<i>Micrococcus luteus</i> A270	1.94 (2.84)
Gram-negative bacteria	
<i>Escherichia coli</i> D31	ND
Fungi	
<i>Aspergillus niger</i>	45.5 (31.01)
Yeast	
<i>Cryptococcus neoformans</i> VNI (WM 148)	22.75 (15.51)

MIC, minimum inhibitory concentration ($\mu\text{g/mL}$): μM . ND, not detectable (antimicrobial activity not detected in the concentrations assayed). ¹The MIC refers to the concentration necessary to achieve a growth inhibition of 100%.

Hemolytic Activity

To determine the effect of the Ovipin peptide on human erythrocytes at the antimicrobial concentrations, its hemolytic activity was tested. After incubating red blood cells from a healthy donor with Ovipin (124.05 μM up to 0.24 μM) concentrations for 1 h at 37 °C. No hemolytic activity was observed, demonstrated that Ovipin does not cause significant hemolytic effect against of human erythrocytes within these concentrations (**Figure 2**) (Yacoub et al., 2014). And the electrophoretic profile (data not show) of this peptide (up to 455 μg) could not observe bands in this gel concentration (12% polyacrilamide).

FIGURE 2 | Hemolytic Activity of the Ovipin peptide incubated with human erythrocytes in different concentrations of the peptides. Serial dilution and duplicated was performed, for 1 h at 37°C. The hemolysis percentage was expressed in relation to 0% hemolysis with PBS and 100% lysis control (0.1% triton X-100)

Mass Spectrometry and Characterization of Ovipin Peptide

When analyzed the Ovipin peptide using the MASCOT® software to search the *Gallus gallus* database, revealed a mass of 1,581.9494 Da and with high identity with a fragment from the Apolipoprotein B (Apo-B) of *Gallus gallus*. The complete Ovipin aa sequence obtained by PEAKS *de novo* sequencing showed 15 amino acid sequence do not having post-translational modification (PTM). Collision-induced dissociation (CID) spectrum from mass/charge (m/z) of its double charged ion give $[M + 2H]^2+$, m/z 792.3484 (**Figure 5**). Characterizing the peptide's primary structure with the MASCOT tool gave the YVSPVAIVKGLNIPL sequence.

MASCOT Search Results

Peptide View

MS/MS Fragmentation of **YVSPVAIVKGLNIPL**

Found in **F1NV02** in **Gallus gallus**, Apolipoprotein B OS=Gallus gallus GN=APOB PE=4 SV=2

▼1 F1NV02 40 Apolipoprotein B OS=Gallus gallus GN=APOB PE=4 SV=2

		Score	Mass	Matches	Sequences	emPAI	
1.1	🔗F1NV02	40	524537	1 (1)	1 (1)	0.01	Apolipoprotein B OS=Gallus gallus GN=APOB PE=4 SV=2
	▶ 1 same set of F1NV02						

▼1 peptide matches (1 non-duplicate, 0 duplicate)

☒ Auto-fit to window

Query	Dupes	Observed	Mr(expt)	Mr(calc)	Delta M	Score	Expect	Rank	U	Peptide
🔗1348		792.3484	1582.6822	1581.9494	0.7328	0	40	0.03	▶1	U D YVSPVAIVKGLNIPL S

Figure 3: Result obtained in searches databases using the tool Mascot® (Matrix Science). The Ovipin peptide is similar with a fragment from the *Gallus gallus* Apolipoprotein B (APO B)

>tr|F1NV02|F1NV02_CHICK Apolipoprotein B OS=Gallus gallus OX=9031 GN=APOB PE=4 SV=2

```

1  MGPVQLLLLL LLLSSGVLTD EGTPEGNNGP CSKDARFES LRKYVLYEA ETSSGITGTA DSHSGSKITC KVELEVPQLC QFILRTMHCS
91  LRETFGVDSE RRAMLKSKN SDDFANAMSK HELRFSTQDG TKVKLYPEKD EPLNVLNLKR GIISALLAPT ETEENIKTIS MDTVYGKCD
181  EVEFKSRRGS VAEDISINRN LKACDNFSPI RDYVSPVAIV KGLNIPLSTL LSSTQSCHYS IDAKKKHIRD VVCSEKHLFL PSSYKNQYGM
271  MTEVNQTLKL EDNQRMNRRN PDGDELEEEKG LALESTDAKF SRQGDVAVLKI LQELQKLTA QNQQRKALF YKFVSGLRSL HNSTLGS
361  KMMETSSSIT IQALIQCGTP ECYSAVLQIL RTGNVNPLVV DLVYTLGLL PSPTPKRIRE ILNMAQYQPS RASFYGLSHA VTKFYSEKMI
451  VTEEITDVAE FMVSLGTDG SGDAELTYLT LRAIGNMGAV MEKAKPSLKA SLKTCIRNQA ASLSVQKAAI QAFRKMITE EDRSALLKEF
541  QEGDAPTDKR LATYLILMKN PSPADLAKIM RILTREKNEQ VKSEFASHIA NILDSEVGI EDLKSHVEEA LKGNEVPYAK DFRKFSQNYQ

```

Figure 4: Peptide spectrum match indicated by a blue line below the sequence of the Apolipoprotein B of *Gallus gallus*. Ovipin covered 2% of the whole protein sequence.

Figure 5: Collision-induced dissociation (CID) spectrum of *de novo* sequencing antimicrobial peptide, Ovipin. The ions belonging to $-y$ (red) and $-b$ (blue) series indicated in the spectrum correspond to the amino acid sequence of the peptide: YVSPVAIVKGLNIPL. The fragments of the sequenced peptide are represented by standard amino acid code letters.

Knowing the sequence, some tools were used predicting Ovipin significant physicochemical characteristics. ExPASy's (SIB Bioinformatics Resource Portal) PepDraw and Pep-Calc.com sequence analysis yielded a potential peptide isoelectric point (pI), molar extinction coefficient and net (Table 3).

The peptide was predicted to have one Lys positively-charged aa residue and six of the 15 aa were predicted to be hydrophobic (2 Ile, 2 Leu and 3 Val), showed hydrophobic ratio of 53% and suggesting poor water solubility for Ovipin. ExPASy's ProtParam tool predicted that the peptide would intact for up 2.8 hours in mammalian reticulocytes (*in vitro*), 10 min in yeast (*in vivo*) and 2 min in *Escherichia coli* (*in vivo*). This was likely due to the presence of a Tyr (Y) residue at the N-terminus.

Table 3: Ovipin theoretical physicochemical properties.

Peptide Properties	
Sequence:	YVSPVAIVKGLNIPL
Length:	15
Mass:	1581.9494
Isoelectric point (pI):	9.49
Net charge at pH:	1
Hydrophobicity:	+ 7.11 Kcal*mol ⁻¹
Estimated solubility:	Poor water solubility
Extinction coefficient:	1280 M ⁻¹ cm ⁻¹

Physicochemical parameters were calculated using ExPASy PepDraw and Pep-Calc.com

A BLAST (basic local alignment search tool) was used to identify a multiple alignment analysis of the peptide sequence Ovipin using Clustal Omega program. The BLAST searches and the alignments showed 100% sequence similarity with the fragment Apolipoprotein B of *Gallus gallus*, and 93.3% of similarity with fragments Apolipoprotein B with others five species of Aves, being *Patagioenas fasciata monillis*, *Amazona aestiva*, *Tinamus guttatus*, *Aptenodytes forsteri* and *Egretta garzetta* (Figure 6).

Origin	Name	Sequence	% Identity
<i>Gallus gallus</i>	Ovipine	---YVSPVAIVKGLNIPL---	15
<i>Gallus gallus</i>	Apolipoprotein	IRDYVSPVAIVKGLNIPLSTL	21 100
<i>Patagioenas fasciata monillis</i>	Apolipoprotein B-100	TRDYVSPVAIVKGLNIPLSTL	21 93.3
<i>Amazona aestiva</i>	Apolipoprotein B-100	IRDYVSPVAIVKGLNIPLSTL	21 93.3
<i>Tinamus guttatus</i>	Apolipoprotein B-100	IRDYVSPVAIVKGLNIPLSTL	21 93.3
<i>Aptenodytes forsteri</i>	Apolipoprotein B-100	IRDYVSPVAIVKGLNIPLSTL	21 93.3
<i>Egretta garzetta</i>	Apolipoprotein B-100	IRDYVSPVAIVKGLNIPLSTL	21 93.3
		****.*****	

Figure 6: Alignment of the amino acid sequence of Ovipin. Using the Clustal Omega alignment, the Ovipin sequence was aligned with fragments of the Apolipoproteins of the *Gallus gallus* and others Aves species. Regions that show identical amino acid among all species are identified in dark red or (*), and minor modifications are show in light red (:). Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalol/>; accessed on 24 January 2020) modified manually.

Table 4. Known antimicrobial peptides having similarity with Ovipin, as identified in the Antimicrobial Peptide Database (APD2) (Wang et al., 2009).

Peptide Name	Sequence Alignment	Source Organism	APD Identifier	Percentage Similarity
Temporin-1SKa (17 aa)	FLPVILPV+IGKLLNGI+L ++YV+SPVAIVKGLN+IPL	Frog <i>Rana sakuraii</i>	AP01924	47,36
Temporin-1GY (13 aa)	+VIP++IVSGLLSLL YVSPVAIVKG+LNIPL	Frogs <i>Pelophylax nigromaculatus</i>	AP02223	43,75
Temporin-1TGc (17 aa)	FLPVILPV+IGKLLSGI+L ++YV+SPVAIVKGL+NIPL	<i>Rana sakuraii</i>	AP01268	42,1
Peptide AN5-1 (12 aa)	YSKSLP+LSV++LN+P+ Y+VS+PVAIVKGLNIPL	<i>Paenibacillus alvei</i> AN5	AP02193	41,17

The Antimicrobial Peptide Database (APD) prediction tool was used to align Ovipin

4. Discussion

The abundance of multidrug-resistance of the microorganisms has emerged, increasing the spectrum of untreatable infections and triggering a worldwide public health problem (**Gaglione et al., 2011; Blair et al., 2015**). The accelerated growth of antimicrobial resistance has created a great interest in the discovery for new compounds more effective, mainly with antimicrobial action, to be used as tools for antimicrobial therapies (**Diaz-Roa et al., 2018; Chernysh et al., 2015**).

During the hatched time, eggs are constantly attacked by a variety of microorganisms that decrease their chances of survival and viability. (**Packard & Packard, 1980**). The compounds isolated from eggs showed a broad spectrum of antimicrobial activity, mainly against bacteria's (**D'Alba & Shawkey, 2015**). In the present work we isolated and characterize a peptide, denoted Ovipin, from chicken eggs *Gallus gallus domesticus*, its antimicrobial activity, biochemical and structural properties were evaluated.

Ovipin presented a good antimicrobial activity (MIC = 1.94 μ M (2.84 μ g/mL)) against *Micrococcus luteus* (Gram-positive bacteria). In the work of **Memarpoor-Yazdia and Chamania (2012)**, was identified from hydrolyzed lysozyme, the F2 peptide (MW 1753.98 Da) that was active against *Leuconostoc mesenteroides* (Gram-positive bacteria) and *Escherichia coli* (Gram-negative bacteria). **Mine et al. (2004)** also isolated and identified from hydrolyzed lysozyme, the peptide F1d (MW 1185 Da), with antimicrobial activity against *Escherichia coli* K-12, and the peptide F3b (MW 875 Da) that was active against *Staphylococcus aureus* 23-394 (Gram-positive bacteria).

Ovipin showed antimicrobial activity against *Aspergillus niger* (MIC = 45.5 μ M (31.01 μ g/mL)) and *Cryptococcus neoformans* strain (MIC = 22.75 μ M (15.51 μ g/mL)). The antimicrobial activity against *C. neoformans* was very interesting, because this yeast belongs to Basidiomycota phylum, and it is founded in avian excreta (mainly from pigeons) and has a strong relationship with human infections with highly incidence in immunocompromised individuals or individual that has some specific defects in immunity. According to the host's immune response, this microorganism can make changes in the metabolism itself as well as induce changes in the structure of its capsule, resulting in multidrug resistance, thus the obtaining of a molecule isolated from a food source and with the ability to inhibit this microorganism of great medical importance may result in a future candidate against infections developed by resistant microorganisms, such as *C. neoformans* (**Srinkanta et al., 2014; Aspaugh, 2015**). In the work **Candido-Ferreira et al. (2017)** was identified and characterized the Oligoventin peptide (8 amino acid residues and MW 1,061.4 Da) from the eggs of the Brazilian armed spider *Phoneutria nigriventer* (Ctenidae, Araneomorphae). Oligoventin showed antimicrobial activity (MIC range at 47 to 188.9 μ M) against

Gram-positive and Gram-negative bacteria, as also yeast (*Candida albicans* MDM8). The molecule shows 4,3% of hemolysis against human erythrocytes at 188.9 μ M and 2% at 94.5 μ M. Therefore, it is worth pointing out that both Ovipin and Oligoventin, although isolated from eggs of different animals, have antimicrobial action against opportunistic pathogens of great medical importance.

Ovipin showed to have 1,581.9494 Da and similarity of 93.3 to 100% with Apolipoproteins B of the five groups of Aves. Very low-density lipoproteins (VLDL) are precursors low-density lipoproteins (LDL) of eggs yolk. VLDL II and apo B are mainly proteins that constituted VLDL. The molecular weight of apo B is 500 kDa, showed only one structural unit and 64% of the similarity with human apo B-100. When transferred into the yolk, the apo B undergoes enzymatic cleavages, forming new fragments (Jolivet *et al.*, 2006), which may have new functions in the yolk.

The apolipoproteins are recognized as source bioactive-peptides showed broad antimicrobial or antiviral activity (Gaglione *et al.* (2017). In the work Zambrovicz *et al.*, (2015) was identified four peptides with molecular weight ranging from 1,210.62 to 1,677.88 Da obtained from Apolipoproteins B, Vitellogenin-2 and Apovitellenin-1, all proteins localized in chicken egg yolk. In relation the peptides identified from Apolipoprotein B, one peptide showed amino acid sequence YINQMPQKSRE (MW: 1,393.774 Da) and the other peptide showed amino acid sequence YINQMPQKSREA (MW: 1,464.813). In this study not was evaluated the antimicrobial activity this peptides, but was demonstrated the antioxidant activity, ACE inhibitory and/or antidiabetic activities. The peptide YINQMPQKSRE demonstrated the strongest antioxidant, and the DPPH free radical scavenging and iron chelating activities reached 2.3 μ M Trolox eq/mg and 37.4 μ g Fe²⁺/mg, respectively. The peptide showed YINQMPQKSREA the highest ferric reducing activity (76.0 μ g Fe²⁺/mg), an activity very strong ACE (IC₅₀ = 10.1 μ g/mL) and DPP-IV (IC₅₀ = 222.8 μ g/mL) inhibitory activity. So, even though the antimicrobial activity of these peptides has not been evaluated, they have important biological activities that can be used as possible multifunctional candidates.

5. Conclusions

The identification and characterization of new antibiotics agents can lead to the development of new compounds that act against resistant pathogenic microorganisms. In this work, we isolated, purified and characterized Ovipin peptide from the chicken eggs *Gallus gallus*

domesticus. The peptide has a molecular weight of 1,581.9494 Da and was able to inhibit the growths of Gram-positive bacteria, Filamentous fungi and Yeast.

Further studies are needed to evaluate the action of this peptide against other pathogenic microorganisms, such as bacteria, fungi, viruses and parasites, as well as to investigate its mechanism of action, if it has antioxidant activity and activity against ACE.

Finally, in addition to their great contribution to food, chicken eggs have become increasingly important in the discovery of new peptides that act against antimicrobial resistance, as well as other important biological activities, they can be used as tools for areas of biotechnology and pharmacology.

Author Contributions: Conceptualization, SRS, AM and PISJ; Data curation, SRS; Formal analysis, AM and PISJ; Funding acquisition, AM and PISJ; Investigation, SRS; Methodology, AM and PISJ.; Project administration, AM and PISJ; Resources, PISJ; Supervision, PISJ and AM; Validation, SRS, AM and PISJ; Writing-original draft, SRS; Writing-review and editing, SRS, AM and PISJ.

Funding: This work was supported by the Research Support Foundation of the State of São Paulo (FAPESP/CeTICS) [Grant No. 2013/07467-1]; the Brazilian National Council for Scientific and Technological Development (CNPq) [Grant No. 472744/2012-7]; and the Coordination for the Improvement of Higher Education Personnel (CAPES) [Grant No. 1646478].

Ethical Approval: This research was approved and performed in accordance with the Ethical Principles in Animal Research adopted by the Ethics Committee for the Use of Animals of UNIFESP - CEUA No 9183300118 and Plataforma Brasil CAAE N° 18794419.7.0000.0065 and was approved.

Data Availability Statement: The data that support the findings of this study are presented in the main manuscript or in the supplementary material of this article.

Acknowledgments: We would like to thank Caroline Correa, Marta Gomes, Rogerio Lauria and Sinval Gregorio laboratory technicians from the Biophysics Department at Unifesp for all their help with peptide synthesis. Professor Dr. Edgar Julian Paredes Gamero, and his students Heron and Wagner at Unifesp, for the opportunity to learn about the development of the antitumor study. *Cryptococcus neoformans* VNI (WM148) was kindly provided by Dra Márcia Melhem - Instituto Adolfo Lutz - São Paulo/SP, Brasil.

Conflicts of Interest: "The authors declare no conflict of interest".

References

- Andreu, D. e Rivas, L. Animal antimicrobial peptides: an overview. *Biopolymers*, 47 (6) 415-433 (1998).
- Anthis, N.J.; Clore, G.M. Sequence-specific determination of protein and peptide concentrations by absorbance at 205 nm. *Protein Sci.* **2013**, 22, 851–858.
- Antimicrobial-peptide-database. Available online: http://aps.unmc.edu/AP/prediction/prediction_main.php (accessed on 12 September 2020).
- Aspaugh, J.A. Virulence mechanisms and *Cryptococcus neoformans* pathogenesis. *Fungal Genet Biol.* 2015 May ; 78: 55–58. doi:10.1016/j.fgb.2014.09.004.
- Bahar, A.A.; Ren, D. Antimicrobial peptides. *Pharmaceuticals (Basel)*, 6 (12) 1543-1575 (2013).

- 44 Brogden, K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol*, 3 (3) 238-
45 250 (2005).
- 46
- 47 Bulet, P. Strategies for the discovery, isolation, and characterization of natural bioactive peptides from the immune
48 system of invertebrates. *Methods Mol. Biol.* **2008**, 494, 9–29. [CrossRef] [PubMed]
- 49
- 50 Bulet, P., Dimarcq, J.L., Hetru, C., Lagueux, M., Charlet, M., Hegy, G., Van Dorsselaer, A. e Hoffmann, J.A. A novel
51 inducible antibacterial peptide of *Drosophila* carries an O-glycosylated substitution. *J Biol Chem*, 268 (20) 14893-
52 14897 (1993).
- 53
- 54 Candido-Ferreira, I.L.; Kronenberger, T.; Sayegh, R.S.R.; Batista, I.F.C.; Silva Junior, P.I. Evidence of an
55 antimicrobial peptide signature encrypted in HECT E3 ubiquitin ligases. *Front Immunol* 2017 Jan 9;7:664. doi:
56 10.3389/fimmu.2016.00664. eCollection 2016.
- 57
- 58 Chambers, M.C., Maclean, B., Burke, R., Amodei, D., Ruderman, D.L., Neumann, S., Gatto, L., Fischer, B., Pratt, B.,
59 Egertson, J., Hoff, K., Kessner, D., Tasman, N., Shulman, N., Frewen, B., Baker, T.A., Brusniak, M.Y., Paulse, C.,
60 Creasy, D., Flashner, L., Kani, K., Moulding, C., Seymour, S.L., Nuwaysir, L.M., Lefebvre, B., Kuhlmann, F., Roark, J.,
61 Rainer, P., Detlev, S., Hemenway, T., Huhmer, A., Langridge, J., Connolly, B., Chadick, T., Holly, K., Eckels, J.,
62 Deutsch, E.W., Moritz, R.L., Katz, J.E., Agus, D.B., MacCoss, M., Tabb, D.L. e Mallick, P. A cross-platform toolkit for
63 mass spectrometry and proteomics. *Nat Biotechnol*, 30 (10) 918-920 (2012).
- 64
- 65 Cruz, J., Ortiz, C., Guzman, F., Fernandez-Lafuente, R. e Torres, R. Antimicrobial peptides: promising compounds
66 against pathogenic microorganisms. *Curr Med Chem*, 21 (20) 2299-2321 (2014).
- 67
- 68 Diaz-Roa, A., Patarroyo, M.A., Bello, F.J. e Da Silva, P.I., Jr. Sarconesin: *Sarconesiopsis magellanica* Blowfly Larval
69 Excretions and Secretions With Antibacterial Properties. *Front Microbiol*, 9 2249 (2018).
- 70
- 71 Ercan, D. e Demirci, A. Recent advances for the production and recovery methods of lysozyme. *Crit Rev Biotechnol*,
72 36 (6) 1078-1088 (2016).
- 73
- 74 Gaglione R, Dell'Olmo E, Bosso A, Chino M, Pane K, Ascione F, Itri F, Caserta S, Amoresano A, Lombardi A,
75 Haagsman HP, Piccoli R, Pizzo E, Veldhuizen EJA, Notomista E, Arciello A. Novel human bioactive peptides identified
76 in Apolipoprotein B: Evaluation of their therapeutic potential. *Biochem Pharmacol*. 2017 Apr 15;130:34-50. doi:
77 10.1016/j.bcp.2017.01.009. Epub 2017 Jan 25. PMID: 28131846.
- 78
- 79 Garcia, F.; Villegas, E.; Espino-Solis, G.P.; Rodriguez, A.; Paniagua-Solis, J.F.; Sandoval-Lopez, G.; Possani, L.D.;
80 Corzo, G. Antimicrobial peptides from arachnid venoms and their microbicidal activity in the presence of commercial
81 antibiotics. *J. Antibiot.* **2013**, 66, 3–10. [CrossRef] [PubMed]
- 82
- 83 Gasteiger, E.; Hoogland, C.; Gattiker, A.; Duvaud, S.; Wilkins, M.R.; Appel, R.D.; Bairoch, A. Protein Identification and
84 Analysis Tools on the ExPASy Server. In *The Proteomics Protocols Handbook*; John, M.W., Ed.; Humana Press Inc.:
85 Totowa, NJ, USA, 2005; pp. 571–607.
- 86
- 87 Gil-Chávez, G.J.; Villa, J.A.; Ayala-Zavala, F.; Heredia, J.B.; Sepulveda, D.; Yahia, E.M.; González-Aguilar, G.A.
88 Technologies for Extraction and Production of Bioactive Compounds to be Used as Nutraceuticals and Food
89 Ingredients: An Overview. *Comprehensive Reviews in Food Science and Food Safety*, January (2013) Vol.12, Issue1,
90 Pages 5-23.
91 <https://doi.org/10.1111/1541-4337.12005>
- 92
- 93 Guimarães, D.O.; Momesso, L. S.; Pupo, M.T. Antibiotics: therapeutic importance and perspectives for the discovery
94 and development of new agents Quim. Nov. Vol. 33, N° 3, São Paulo, (2010). [http://dx.doi.org/10.1590/S0100-](http://dx.doi.org/10.1590/S0100-40422010000300035)
95 40422010000300035
- 96
- 97 Hancock, R.E. e Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat*
98 *Biotechnol*, 24 (12) 1551-1557 (2006).
- 99
- 00 Hetru, C.; Bulet, P. Strategies for the isolation and characterization of antimicrobial peptides of invertebrates. *Methods*
01 *Mol. Biol.* **1997**, 78, 35–49. [CrossRef]
- 02

- Ibrahim, H.R., Sugimoto, Y. e Aoki, T. Ovotransferrin antimicrobial peptide (OTAP-92) kills bacteria through a membrane damage mechanism. *Biochim Biophys Acta*, 1523 (2-3) 196-205 (2000).
- Izadpanah A, Gallo RL. Antimicrobial peptides. *J Am Acad Dermatol*. 2005;52(3 Pt 1):381-392. doi:10.1016/j.jaad.2004.08.026
- Jolivet, P.; Boulard, C.; Beaumal, V.; Chardot, T.; Anton, M. Protein components of low-density lipoproteins purified from hen egg yolk. *J. Agric. Food Chem.*, 2006, 54, 4424-4429.
- Kang, S.J., Park, S.J., Mishig-Ochir, T. e Lee, B.J. Antimicrobial peptides: therapeutic potentials. *Expert Rev Anti Infect Ther*, 12 (12) 1477-1486 (2014).
- Kolaczowska, A., Kolaczowski, M., Sokolowska, A., Miecznikowska, H., Kubiak, A., Rolka, K. e Polanowski, A. The antifungal properties of chicken egg cystatin against *Candida* yeast isolates showing different levels of azole resistance. *Mycoses*, 53 (4) 314-320 (2010).
- Kovacs-Nolan, J., Phillips, M. e Mine, Y. Advances in the value of eggs and egg components for human health. *J Agric Food Chem*, 53 (22) 8421-8431 (2005).
- Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* (1970), 227, 680–685. [CrossRef] [PubMed]
- Li J, Koh JJ, Liu S, Lakshminarayanan R, Verma CS, Beuerman RW. Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. *Front Neurosci*. 2017;11:73. Published 2017 Feb 14. doi:10.3389/fnins.2017.00073
- Lorenzini, D. M., Da Silva, P. I. Jr., Fogaca, A. C., Bulet, P., and Daffre, S. (2003). Acanthoscurrin: a novel glycine-rich antimicrobial peptide constitutively expressed in the hemocytes of the spider *Acanthoscurria gomesiana*. *Dev. Comp. Immunol*. 27, 781–791. doi: 10.1016/S0145-305X(03)00058-2
- Memarpoor-Yazdia, M.A., A.; Chamania, J. A novel antioxidant and antimicrobial peptide from hen egg white lysozyme hydrolysates. *Journal of Functional Foods*, 4 (1) 278-286 (2012).
- Mookherjee, N.; Hancock, R.E.W. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. *Cell. Mol. Life Sci*. 64 (2007) 922 – 933. DOI 10.1007/s00018-007-6475-6
- Perkins, D.N., Pappin, D.J., Creasy, D.M. e Cottrell, J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. *Electrophoresis*, 20 (18) 3551-3567 (1999).
- Peters, B.M.; Shirtli_, M.E.; Jabra-Rizk, M.A. Antimicrobial Peptides: Primeval molecules or future drugs? *PLoS Pathog*. 2010, 6, e1001067. [CrossRef] [PubMed]
- Riciluca, K.C., Sayegh, R.S., Melo, R.L. e Silva, P.I., Jr. Rondonin an antifungal peptide from spider (*Acanthoscurria rondoniae*) haemolymph. *Results Immunol*, 2 66-71 (2012).
- Rutherford-Markwick KJ. Food proteins as a source of bioactive peptides with diverse functions. *Br J Nutr*. 2012;108 Suppl 2:S149-S157. doi:10.1017/S000711451200253X
- Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. *Biochim Biophys Acta*, 1462 (1-2) 55-70 (1999).
- Segura-Ramírez PJ, Silva Júnior PI. *Loxosceles gaucho* Spider Venom: An Untapped Source of Antimicrobial Agents. *Toxins (Basel)*. 2018;10(12):522. Published 2018 Dec 6. doi:10.3390/toxins10120522
- Silva, P.I., Jr., Daffre, S. e Bulet, P. Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider *Acanthoscurria gomesiana* hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family. *J Biol Chem*, 275 (43) 33464-33470 (2000).
- Srikanta, D.; Santiago-Tirado, F.H.; Doering, T.L. *Cryptococcus neoformans*: Historical curiosity to modern pathogen. *Yeast*. 2014 February ; 31(2): 47–60. doi:10.1002/yea.2997.

Wang, G.; Li, X.; Wang, Z. APD2: The updated antimicrobial peptide database and its application in peptide design. *Nucleic Acids Res.* **2009**, 37, 933–937.

Zambrowicz, A.; pokora, M.; Setner, B.; Dabrowska, A.; Szoltysik, M.; Babij, K.; Szewczuk, Z.; Trziszka, T.; Lubec, G.; Chrzanowska, J. Multifunctional peptides derived from an egg yolk protein hydrolysate: isolation and characterization. *Amino Acids* **47**, 369–380 (2015). <https://doi.org/10.1007/s00726-014-1869-x>

Zasloff, M. Antimicrobial peptides of multicellular organisms. *Nature*, 415 (6870) 389-395 (**2002**).

1. online: URL (accessed on Day Month Year).